TRAF3IP2 antibody (AA 1-565)
The Mouse Polyclonal anti-TRAF3IP2 antibody has been validated for WB. It is suitable to detect TRAF3IP2 in samples from Human.
Quick Overview for TRAF3IP2 antibody (AA 1-565) (ABIN948986)
Target
See all TRAF3IP2 Antibodies
TRAF3IP2
(TRAF3 Interacting Protein 2 (TRAF3IP2))
Reactivity
Human
Host
Mouse
Clonality
Polyclonal
Conjugate
This TRAF3IP2 antibody is un-conjugated
Application
Western Blotting (WB)
-
-
Binding Specificity
-
AA 1-565
-
Purpose
-
Mouse polyclonal antibody raised against a full-length human TRAF3IP2 protein.
-
Sequence
-
MNRSIPVEVD ESEPYPSQLL KPIPEYSPEE ESEPPAPNIR NMAPNSLSAP TMLHNSSGDF SQAHSTLKLA NHQRPVSRQV TCLRTQVLED SEDSFCRRHP GLGKAFPSGC SAVSEPASES VVGALPAEHQ FSFMEKRNQW LVSQLSAASP DTGHDSDKSD QSLPNASADS LGGSQEMVQR PQPHRNRAGL DLPTIDTGYD SQPQDVLGIR QLERPLPLTS VCYPQDLPRP LRSREFPQFE PQRYPACAQM LPPNLSPHAP WNYHYHCPGS PDHQVPYGHD YPRAAYQQVI QPALPGQPLP GASVRGLHPV QKVILNYPSP WDQEERPAQR DCSFPGLPRH QDQPHHQPPN RAGAPGESLE CPAELRPQVP QPPSPAAVPR PPSNPPARGT LKTSNLPEEL RKVFITYSMD TAMEVVKFVN FLLVNGFQTA IDIFEDRIRG IDIIKWMERY LRDKTVMIIV AISPKYKQDV EGAESQLDED EHGLHTKYIH RMMQIEFIKQ GSMNFRFIPV LFPNAKKEHV PTWLQNTHVY SWPKNKKNIL LRLLREEEYV APPRGPLPTL QVVPL
-
Cross-Reactivity
-
Human
-
Characteristics
-
Antibody reactive against mammalian transfected lysate.
-
Immunogen
-
TRAF3IP2 (NP_679211.1, 1 a.a. ~ 565 a.a) full-length human protein.
-
-
-
Application Notes
-
Optimal working dilution should be determined by the investigator.
-
Restrictions
-
For Research Use only
-
-
Buffer
-
In 1x PBS, pH 7.4
-
Handling Advice
-
Aliquot to avoid repeated freezing and thawing.
-
Storage
-
-20 °C
-
Storage Comment
-
Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
-
Target
-
TRAF3IP2
(TRAF3 Interacting Protein 2 (TRAF3IP2))
-
Alternative Name
-
TRAF3IP2
-
Background
-
Full Gene Name: TRAF3 interacting protein 2
Synonyms: ACT1,C6orf2,C6orf4,C6orf5,C6orf6,CIKS,DKFZp586G0522,MGC3581
-
Gene ID
-
10758
-
NCBI Accession
-
NM_147686
-
Pathways
-
Production of Molecular Mediator of Immune Response
-